Sitemap

Posts

• Category: contact
  • API Sales and Marketing
  • Contract Research and Manufacturing Services
  • For Raw Material Supplies to Parabolic Drugs Limited
  • Investor Relation and Corporate Communication
• Category: Health-wellness
  • All About Antibiotics: 22 Answers to Important Questions
  • How Can I Get Cheaper Medications?
• Category: imp links
  • Analyst Corner
• Category: pr1
  • From a small contract manufacturer to a reliant partner for the innovator companies
• Category: Uncategorized
  • BTS India Private Equity invests in Parabolic Drugs Limited
  • Draft red herring prospectus filed on March 3rd, 2006
  • Minivet, a Mauritius based FII picks up 4.93% stake in PDL
  • Parabolic Accredited with ISO 14001 Certification
  • Parabolic Drugs Limited acquires land in Baddi, Himachal Pradesh for putting up a dosage facility
  • Parabolic Drugs Limited get approval from Ranbaxy for supply of regulated 6 APA for Ranbaxy’s US markets from PDL’s Panchkula facility, subsequent to PDL filing DMF for USFDA approval in 2005.
  • PDL commission’s
  • PDL received Certificate of suitability from the office of European Directorate for the Quality of Medicines & HealthCare, France
  • PDL's Panchkuls facility is USFDA approved
  • WHO-GMP Accreditation For Parabolic Cephalosporin Facility

Pages

• About Us
• Accreditations
• Annual Accounts of Subsidiary
• Annual Reports
• API
• Arun Mathur
• Board Of Directors
• Business Model
• Capabilities
• Careers
• Careers Application
• CIRP Notification
• Company Overview >> Key Strengths
• Contact CRAMS Division
• Contact IR
• Contact Nucleus
• Contact Us
• Contract Manufacturing
• Contract Research
• Corporate Governance
• CRAMS
• CSR
• Current Openings
• Domestic Presence
• DR. ARVIND KUMAR MISHRA
• Dr. Ram Kumar
• Dr.(Mrs) Deepali Gupta
• DR.PARVEN KUMAR LUTHRA
• Environment Initiatives
• EVENTS SPONSORED BY PARABOLIC DRUGS LIMITED
• Financials
• Global Presence
• Health and Safety
• Home
• HR at PDL
• HR Goals
• HR Vision
• Infrastructure
• International Business
• Introduction
• Investor Relations
• IPRQA and QC
• K.Srinivas
• Key Financial Indicators
• Key Growth Drivers
• Key Milestones
• Latest Financial Results
• Management Team
• Manufacturing Facilities
• Market Presence
• Markets and Customers
• MD’s Address
• Mission
• Month: December 2017
• Month: September 2018
• Mr. Ajeet Nigam
• Mr. Pardeep Diwan
• News
• News Archives
• Our Products
• Our Vision
• Parabolic Drugs in News
• Privacy policy
• Product: CEPHALOSPORIN – ORAL
• Product: CEPHALOSPORIN – STERILE
• Product: SEMI SYNTHETIC PENICILLINS - ORAL
• Product: SEMI SYNTHETIC PENICILLINS – STERILE
• Products
• Public Issue
• RD
• Recent CSR Initiatives at Parabolic Drugs Limited
• Regulatory Affairs
• Research and Development Centre- Barwala
• Research and Development Lab- Derabassi
• Segments
• Shareholding Pattern
• Sitemap
• Strategic Partnerships for Global Marketing
• Track PDLs Share
• Upload Your CV
• Valuing Our Society
• Vision
• Why Parabolic Drugs Limited?